VHL, NT (Von Hippel-Lindau Disease Tumor Suppressor, pVHL, Protein G7)

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.\n\nApplications: \nSuitable for use in ELISA and Western Blot. Other applications not tested.\n\nRecommended Dilution:\nELISA: 1:1,000\nWestern Blot: 1:50-1:100\nOptimal dilutions to be determined by the researcher.\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

V2640-03H

Size

200ul

Applications

ELISA, WB

Hosts

Rabbit

Reactivities

Hum

Form

Supplied as a liquid in PBS, 0.09% sodium azide.

P Type

Pab

Purity

Purified by Protein G affinity chromatography.

Isotype

IgG

References

1.Olmos,G., Cell. Mol. Life Sci. 66(13), 2167-2180 (2009). 2.Hatzimichael,E., Clin Lymphoma Myeloma 9(3), 239-242 (2009). 3.Luu,V.D., Clin. Cancer Res. 15(10), 3297-3304 (2009).

Additional Info

Recognizes human VHL.